Key facts
- It has raised $500K across 1 recorded rounds; the latest was Seed Round ($500K) in Feb 2026.
- Notable investors include National Institutes of Health, Peachscore, Lung, National Heart, Peachscore + Gust Accelerator Program — 9 tracked in total.
- Advac Therapeutics has filed 1 Form D with the SEC, most recently Mar 2026 ($500K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Advac Therapeutics
Funding rounds
1 roundsAbout Advac Therapeutics
Developer of vaccines and therapeutics designed for the treatment of infectious diseases and cancers. The company focuses on a portfolio of small-molecule therapeutics that potentially radically change current standards of lung disease treatments, address recovery pneumonia patients, and improve the odds of survival by tackling the development of a novel therapeutic for the regeneration of damaged lung tissue, enabling patients to get proper treatment for improved health.
- Sector
- Healthcare
- HQ
- Columus, OH, United States
- Website
- advactherapeutics.ozcorp.io/
- Ownership
- Privately Held (backing)
Advac Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Advac Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Advac Therapeutics in its N-PORT filings yet. We sweep new filings monthly.